MASH Liver Disease Symptoms: Early Warning Signs
- Emily Shill, RN, BSN
- Mar 28
- 8 min read
Many liver conditions develop quietly, often without obvious warning signs, until the disease has progressed. One condition that has gained increasing medical attention in recent years is metabolic dysfunction-associated steatohepatitis (MASH). Understanding the symptoms of MASH liver disease can help individuals recognize potential warning signs and seek medical care before serious liver damage occurs.
MASH is a more advanced and inflammatory form of fatty liver disease that can eventually lead to liver scarring (fibrosis), cirrhosis, and even liver failure if left untreated. The challenge is that symptoms often appear gradually and may initially seem mild or unrelated to liver health.
Recognizing early symptoms, performing appropriate screening, and understanding risk factors are important steps in protecting long-term liver health.
In this article, Dr. Otto Shill, DO, FACP, DABOM, co-founder of ShillMed, will explore common symptoms, risk factors, and lifestyle adjustments to help mitigate the impact of this condition, ultimately supporting better liver health and well-being.
What Is MASH Liver Disease?
MASH stands for metabolic dysfunction-associated steatohepatitis. It is a condition where fat accumulates in the liver and triggers inflammation and damage to liver cells. MASH is closely related to metabolic health conditions such as the following:
Obesity
Type 2 diabetes
High cholesterol
Insulin resistance
High blood pressure
The disease often develops from metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). While MASLD involves fat buildup in the liver, MASH includes inflammation and liver cell injury, which can lead to scarring over time. Without proper management, MASH can progress to serious liver complications.
To learn more about MASLD, check out this comprehensive clinical overview from the National Library of Medicine.
Ready for a deep dive into the why and how of MASH pathology? Check out this article from the Journal of Clinical Investigation.
In 2023 a multi-society Delphi consensus statement formally changed the name of NASH (non-alcoholic steatohepatitis) to MASH (metabolic dysfunction-associated steatohepatitis) to emphasize the significant contribution of metabolic pathology to the disease state. This also more-clearly differentiated the disease from alcoholic liver disease.
Why MASH Liver Disease Can Be Hard to Detect
One of the most challenging aspects of MASH liver disease is that symptoms often do not appear until the disease has progressed. The liver has a remarkable ability to compensate for damage, which means people may feel relatively normal even when inflammation is present.
This is why many individuals with MASH are diagnosed through routine blood tests or imaging studies rather than through noticeable symptoms.
Early MASH Liver Disease Symptoms
Although symptoms of MASH liver disease may be subtle, several early signs can occur as liver inflammation begins to develop.
Persistent Fatigue: One of the most common MASH liver disease symptoms is unexplained fatigue. Individuals may feel unusually tired even after adequate rest. This fatigue may occur because the liver plays an essential role in energy metabolism. When liver function is compromised, the body may struggle to process nutrients efficiently.
Discomfort in the Upper Right Abdomen: Some people with MASH report a dull ache or discomfort on the right side of the abdomen, where the liver is located. This sensation may result from liver inflammation or enlargement, which can stretch the capsule surrounding the liver.
Brain Fog and Difficulty Concentrating: Cognitive symptoms such as mild brain fog or difficulty concentrating may occur in some cases of liver disease, though more typically as the severity worsens. While these symptoms are not exclusive to MASH, they can sometimes accompany metabolic and inflammatory conditions.
Unexplained Weight Changes: Because MASH is closely tied to metabolic health, some individuals may experience changes in body weight or difficulty losing weight despite lifestyle changes. Weight gain around the abdomen is particularly associated with metabolic liver conditions.
Symptoms That May Develop as MASH Progresses
If liver inflammation continues unchecked, MASH liver disease symptoms may progress to more serious liver damage, including fibrosis (scarring) and eventually cirrhosis. At more advanced stages, additional symptoms may appear:
Yellowing of the Skin or Eyes (Jaundice): Jaundice occurs when the liver struggles to process bilirubin, causing a yellow tint in the skin or eyes.
Swelling in the Abdomen or Legs: Advanced liver disease can cause fluid retention, leading to swelling in the abdomen (ascites) or legs.
Easy Bruising or Bleeding: The liver helps produce proteins responsible for blood clotting. When liver function declines, individuals may bruise more easily as production of these proteins declines.
Severe Fatigue and Weakness: As liver damage progresses, fatigue may become more severe and interfere with daily activities.
Risk Factors for MASH
Certain individuals have a higher risk of developing MASH due to underlying metabolic conditions. Key risk factors include the following:
Obesity
Type 2 diabetes
Insulin resistance
Metabolic Syndrome
High cholesterol
Sedentary lifestyle
Poor dietary habits
Family history of liver disease
People with these risk factors may benefit from routine liver health evaluations even if they do not have noticeable symptoms.
How MASH Is Diagnosed
Because MASH liver disease symptoms alone are not always reliable indicators, physicians typically use several diagnostic tools to identify MASH. These may include the following:
Blood Tests: Blood tests can evaluate liver enzyme levels, which may indicate inflammation or liver injury.
Imaging Studies: Ultrasound, CT scans, or specialized technologies such as FibroScan can help measure liver fat and stiffness.
FibroScan Testing: FibroScan is a non-invasive test that measures liver stiffness and fat content. It helps doctors determine whether fibrosis or significant liver inflammation may be present.
Liver Biopsy: In some cases, a liver biopsy may be recommended to confirm the diagnosis and determine the severity of liver damage.
Managing MASH Liver Disease
The good news is that MASH can often be managed effectively when detected early. Lifestyle changes play a major role in slowing or reversing liver damage.
Weight Management: Even modest weight loss — around 7–10% of body weight — can significantly reduce liver fat and inflammation.
Balanced Nutrition: A healthy diet rich in whole foods can support liver function. Key dietary strategies include increasing vegetable and fruit intake, choosing lean proteins, limiting added sugars and refined carbohydrates, and reducing processed foods.
Regular Physical Activity: Exercise helps improve insulin sensitivity and reduce liver fat. Both aerobic activity and strength training may benefit metabolic health.
Management of Metabolic Conditions: Treating related conditions such as diabetes, high cholesterol, and high blood pressure can also improve liver health.
The Importance of Regular Liver Screening
Because MASH liver disease symptoms may appear late in the disease process, regular screening is extremely important for individuals at risk. Routine medical evaluations may include the following:
Blood tests
Metabolic health assessments
Liver imaging
FibroScan evaluations
Early detection allows physicians to recommend interventions that prevent the progression of liver damage.
The FIB-4 Index: A Simple Strategy for Early Screening
Because MASH liver disease symptoms are often silent, clinicians increasingly rely on the FIB-4 (Fibrosis-4) index as a first-line screening tool. The FIB-4 is a simple, non-invasive calculation used to estimate the amount of scarring (fibrosis) in the liver without the need for an immediate biopsy or expensive imaging.
The FIB-4 is calculated using lab values commonly obtained by primary care doctors on routine and screening lab work including ALT, AST, platelet count, and your age. See this article from the journal Hepatology to learn how scientists derived this formula. Important note: normal lab values do NOT rule out MASH.
How to Interpret FIB-4 Score: A Guide to Liver Fibrosis Screening
The FIB-4 index is a validated, non-invasive screening tool used to estimate the risk of liver scarring (fibrosis). In 2022, the American Association of Clinical Endocrinology (AACE) and the American Association for the Study of Liver Diseases (AASLD) issued joint clinical guidelines for applying the FIB-4 score to identify Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as NASH.
FIB-4 Score Interpretation Chart
For patients with risk factors such as Type 2 diabetes, obesity, or metabolic syndrome, FIB-4 scores are categorized into three clinical risk tiers:
Low Risk (FIB-4 < 1.3): Highly reliable for ruling out advanced fibrosis. Patients in this tier typically continue routine monitoring with a primary care provider.
Indeterminate Risk (FIB-4 1.3 – 2.67): Results are inconclusive and require further diagnostic investigation, such as FibroScan (Vibration-Controlled Transient Elastography/VCTE) or specialized blood tests.
High Risk (FIB-4 > 2.67): Indicates a high probability of advanced fibrosis or cirrhosis. A direct referral to a hepatologist or liver specialist is recommended.
Note: For patients over age 65, some clinical protocols use a higher "Low Risk" cutoff of < 2.0 to account for age-related changes in liver enzymes.
What Happens After a High FIB-4 Score? Cost and Coverage Guide for Liver Fibrosis Diagnostics
Navigating the financial aspect of liver health is a key step in clinical management. While the FIB-4 is a zero-cost screening tool, secondary confirmation tests vary in price and insurance requirements.
Test Name | CPT Code(s) | Typical Cost | Insurance Coverage Notes |
FIB-4 Index | 84450, 84460, 85049 | $0 | Calculated from routine labs; usually no extra charge. |
FibroScan (VCTE) | 91200 / 76981 | $150 – $500 | Widely covered for FIB-4 $\ge$ 1.3 or chronic liver disease. |
ELF™ Test | 81517 | $200 – $400 | Often requires a "reflex" order from a high-risk FIB-4 score. |
FibroSure® | 81599 / 81596 | $250 – $600 | Covered for Hep C; may require prior auth for MASH/MASLD. |
MR Elastography | 76391 | $1,200+ | The premium option; requires documentation of VCTE failure or high BMI. |
Read more about the non-invasive follow-up testing for an elevated FIB-4 score such as FibroScan and advanced biomarkers in this article in the Journal of Gastroenterology and Hepatology.
Why FIB-4 Matters in Clinical Practice
By utilizing the FIB-4 calculation early in the diagnostic process, healthcare providers can identify high-risk patients long before physical symptoms appear. This allows for improved outcomes through early intervention with:
Weight Management: Targeted lifestyle changes to reduce hepatic fat, including FDA-approved GLP-1 medications.
Metabolic Optimization: Managing blood glucose and lipid profiles.
Specialist Referral: Ensuring high-risk patients receive advanced hepatology care.
Common Evidence-Based Treatments for MASH
Both lifestyle (weight loss) and medical therapies play a role in the treatment of MASH. According to the AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease, weight loss plays a significant role:
≥5% Weight Loss: Associated with a reduction in hepatic steatosis (liver fat).
≥7% Weight Loss: Associated with MASH resolution (reduction in inflammation and ballooning).
≥10% Weight Loss: Associated with fibrosis regression or stabilization (reversing scar tissue).
Medical Therapy for MASH
Rezdiffra (resmetirom): a daily oral tablet used with diet and exercise to treat noncirrhotic nonalcoholic steatohepatits (MASH formerly NASH) with moderate to advanced fibrosis, was approved by the FDA in 2024.
Wegovy (semaglutide): a weekly injection used with diet and exercise to treat Stage F2-F3 (moderate to advanced) MASH fibrosis was added to AASLD guidelines in November 2025 following FDA approval for this indication.
Conclusion: Don’t Ignore Possible Liver Symptoms
Understanding the symptoms of MASH liver disease can help individuals recognize potential warning signs before serious liver damage develops. Although the condition often progresses silently, symptoms such as fatigue, abdominal discomfort, and metabolic changes may signal underlying liver inflammation.
The good news is that with early detection and proper medical guidance, many people can significantly improve liver health through lifestyle changes and targeted care.
Taking proactive steps now can help protect liver function and reduce the risk of complications later in life. Contact us today to schedule a consultation and take the first step toward better liver health.
—-------------
About Dr. Otto Shill, DO, FACP, DABOM
Dr. Otto Shill is a board-certified physician, Fellow of the American College of Physicians (FACP), and Diplomate of the American Board of Obesity Medicine (DABOM) specializing in Internal Medicine, metabolic health, fatty liver disease (MAFLD), and medically supervised weight management.
His clinical work focuses on identifying and treating the underlying causes of weight gain—including insulin resistance, hormonal dysregulation, and liver health—using evidence-based strategies that combine lifestyle intervention, nutrition, and when appropriate, pharmacotherapy. Dr. Shill regularly treats patients with fatty liver disease and related metabolic conditions, helping them reverse disease progression and achieve sustainable weight loss.
Through his writing, Dr. Shill breaks down complex topics like the relationship between fatty liver and weight gain into clear, actionable insights grounded in current medical research. He has a particular interest in emerging treatments, including GLP-1–based therapies, and how they impact both liver health and body weight.
Dr. Shill is committed to providing accurate, trustworthy medical information that reflects the latest clinical guidelines and real-world patient outcomes.
Comments